New hope for hard-to-treat breast cancer? drug duo targets PIK3CA mutation
Disease control
Not yet recruiting
This study tests a combination of two drugs (inavolisib and eribulin) in people with advanced triple-negative breast cancer that has a specific genetic change called PIK3CA mutation. The goal is to see if the combo can shrink tumors. About 26 participants who have already tried a…
Phase: PHASE2 • Sponsor: Hu Hai • Aim: Disease control
Last updated May 04, 2026 16:18 UTC